Aaron Kantoff
Co-Founder & Managing Partner at Scion Life Sciences
New York, New York
Skills
Work Experience
2022
Co-Founder & Managing Partner
2022
Board Member
2024
Leading research foundation for the diagnosis and treatment of Pancreatic Cancer
2022
Board Member
2022
Developing transformative medicines that dramatically improve the lives of patients with immune & inflammatory diseases. Lead program, TOUR001, is an anti-IL6L for treatment of autoantibody mediated diseases and inflammatory cardiovascular disorders. NASDAQ: TRML
2020 - 2024
Founding Board Member
2020 - 2024
Targeted Radiotherapy. Acquired by Bristol Myers Squibb for $4.1B.
2020 - 2022
Board Member
2020 - 2022
NASDAQ: CNTA
2020 - 2021
Venture Partner
2020 - 2021
2018 - 2019
Board Member
2018 - 2019
Leading metabolic disease company. Developing a long-acting Fc Fusion modified fibroblast growth factor 21 (FGF21), AKR-001, for NASH and other metabolic diseases. NASDAQ: AKRO
2016 - 2019
Board Member
2016 - 2019
Developing precision medicines for cardiovascular disease Acquired by Novo Nordisk for $2.1B in total cash considerations
Board Member
2015 - 2019
Elstar Therapeutics is leveraging recent technological advances in antibody engineering to generate best-in-class multi-specific and multi-functional immunotherapies. These molecules harness our growing understanding of immune modulation to treat a variety of hematological malignancies and solid tumors.
2011 - 2019
Partner
2011 - 2019
Apple Tree Partners (ATP), is a venture capital firm that invests in and builds biotech companies.